Biosimilars Bring Much-Needed Competition to Drug Markets

1
Biosimilars - Biosimilars on the cusp of a new
era
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE [phone]E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview

• The biosimilars market is undergoing rapid change
  with developments such as the recent approvals of
  infliximab and trastuzumab heralding a new era.
  In order to keep up with the pace of change in
  the marketplace, regulatory agencies have been
  developing updated guidance around the
  development and approval of biosimilars, but
  there is still a lack of consistency,
  particularly between the two leading agencies -
  the FDA and EMA.
• Moreover, there are some concerns around
  biosimilar use, for example with physicians
  worried about how similar certain drugs are and
  whether they can safely be used in particular
  patient populations such as transplant, due to
  the potential for variance in efficacy and
  tolerability. Despite this, it is expected that
  the biosimilar market will continue to experience
  significant growth in the next five to ten years,
  being driven by the extensive pipeline and the
  number of companies becoming involved in this
  area - including some big pharma who are seizing
  the opportunity to develop biosimilar versions of
  competitor products in order to ensure they are
  able to compete at all levels.
• Read More At http//www.researchbeam.com/biosimi
  lars-biosimilars-on-the-cusp-of-a-new-era-market

3


Report Overview

• Scope
• The report covers the following key areas -
• - An overview and background about biosimilars -
  what they are and a timeline of their development
• - Key concerns regarding the development and use
  of biosimilars
• - An overview of the issues around automatic
  substitution with biosimilars
• - The regulatory landscape for biosimilars,
  including a comparison of FDA and EMA guidelines
• - Recent developments in the biosimilars market
  including the anticipated patent expiries of key
  biologic products and launches of new biosimilar
  products
• - The position of HTA and PR agencies on
  biosimilars
• - Industry perspective on the expected impact of
  biosimilars
• - The biosimilars pipeline and key future
  developments
• - Key companies involved in biosimilars
• - The way forward for industry

4


Table of Content
Executive summary Methodology Biosimilars an
overview Key concerns surrounding biosimilar
use Automatic substitution A changing regulatory
landscape EMA guidelines FDA guidelines Considerat
ions for the rest of the world Recent
developments in the biosimilars market New
biosimilar launches Government/agency
opinions Implications for the marketplace The
future outlook The biosimilar pipeline Paradigm-ch
anging potential Key players The way forward for
industry Appendix Enquire At
http//www.researchbeam.com/biosimilars-biosimilar
s-on-the-cusp-of-a-new-era-market/enquire-about-re
port
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/biosimilars-biosimilar
s-on-the-cusp-of-a-new-era-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com